Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $6.2052W HIGH $13.38
Volume
19.03 M
Value Traded
25.30 M
Short % Float
31.82%
+1.51%Week
+37.1%1 Month
+43.1%3 Month
+57.21%6 Month
-93.62%5 Year
-88.49%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
2.10 B
EPS (TTM)
-1.50
P/E Ratio
-
Ent. Value
1.68 B
Total Shares
164.95 M
Float Shares
156.74 M
Insiders
4.97%
Institutions
67.53%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
| Catalyst | Drug / Treatment | Stage | Prob. of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Example Drug Treatment for example condition requiring FDA review | Phase 3 | Small Molecule | Oncology | - |
PoA blends historical approval base rates, trial design score and FDA review track record.
NVAX Catalyst Timeline
Dated clinical, regulatory and corporate events for Novavax, Inc.
Catalyst Timeline
Dated clinical, regulatory & corporate events for Novavax, Inc.
1642Total events
11Upcoming
622Tier-1 (high impact)
2010 to 2027Coverage
Upcoming catalysts 2
Event history 50
▲FDA ApprovalNuvaxovidApprovedFDA Decision
Nuvaxovid XFG-adapted formulation approved in U.S., EU, and Japan for 2026-2027 season
COVID-19source ↗
▲Full ResultsNuvaxovidApprovedClinical Data
Results from Sanofi's Phase 4 COMPARE study demonstrated favorable tolerability profile
COVID-19source ↗
▲Fast Track DesignationSP0335Designation
FDA granted Fast Track designation for SP0335
H5 pandemic influenzasource ↗
●Pre IND MeetingFDA Meeting
Pre-IND interactions with FDA for C. difficile vaccine
C. difficilesource ↗
●Partnership / LicenseMatrix-MCorporate
Multiple partner-led experiments with Matrix-M underway
Various infectious disease and oncologysource ↗
●Pre IND MeetingFDA Meeting
Advanced C. difficile vaccine into pre-IND interactions with FDA
Clostridioides difficile infectionsource ↗
◆Product LaunchPost-Market
Potential combination vaccine launch in fall 2026
COVID-19 and influenzasource ↗
◆Oral PresentationPresentation
Leerink Partners 2026 Global Healthcare Conference Fireside Chat
●Quarterly UpdateCorporate
Q4 and full year 2025 financial results and operational highlights
▲Partnership / LicenseCorporate
Novavax enters into license agreement with Pfizer for Matrix-M adjuvant
◆Oral PresentationPresentation
Novavax presentation at 44th Annual J.P. Morgan Healthcare Conference
▲Partnership / LicenseCorporate
Secured four additional MTAs with large pharma and biotech companies
▲Product LaunchPost-Market
Potential launch of CIC and standalone influenza vaccines in 2026
COVID-19-Influenza Combination and standalone influenzasource ↗
▲Product LaunchNuvaxovidApprovedPost-Market
Sanofi launches Nuvaxovid in Germany, Canada and other international markets from 2026 onward
COVID-19source ↗
◆Milestone PaymentNuvaxovidApprovedCorporate
Up to $50 million in milestone payments for marketing authorization transfers to Sanofi
COVID-19source ↗
◆R&D DayPresentation
Novavax to participate in Jefferies London Healthcare Conference fireside chat
▲Milestone PaymentNuvaxovidApprovedCorporate
Completion of U.S. marketing authorization transfer to Sanofi triggers $25 million milestone payment
COVID-19source ↗
▲Partnership / LicenseNuvaxovidApprovedCorporate
Completion of U.S. marketing authorization transfer to Sanofi under collaboration and license agreement
COVID-19source ↗
▲Milestone PaymentNuvaxovidApprovedCorporate
Completion of EU marketing authorization transfer to Sanofi triggers $25M milestone payment
COVID-19source ↗
▲Milestone PaymentNuvaxovidApprovedCorporate
Completion of EU marketing authorization transfer to Sanofi triggers $25 million milestone payment
COVID-19source ↗
▲Partnership / LicenseNuvaxovidApprovedCorporate
Completion of EU marketing authorization transfer to Sanofi
COVID-19source ↗
▲Partnership / LicenseCorporate
Sanofi license expanded to include Matrix-M adjuvant in pandemic influenza vaccine candidate program
pandemic influenzasource ↗
◆Oral PresentationPresentation
Novavax to participate in Cantor Global Healthcare Conference fireside chat
▲FDA ApprovalNuvaxovidApprovedFDA Decision
Nuvaxovid approved in Japan for initial immunization and booster
COVID-19 (Omicron LP.8.1)source ↗
▲Milestone PaymentNuvaxovidApprovedCorporate
Milestone payment triggered from Takeda upon Japan approval
COVID-19source ↗
▲Partnership / LicenseNuvaxovidApprovedCorporate
Transition of lead commercial responsibility to Sanofi for 2025-2026 season
COVID-19source ↗
▲FDA ApprovalNuvaxovidApprovedFDA Decision
FDA approval of Nuvaxovid 2025-2026 Formula for COVID-19 in high-risk adults and adolescents
COVID-19source ↗
◆Debt Royalty FinancingCorporate
Issued $225M 4.625% Convertible Senior Notes due 2031, including ~$175M exchange of 2027 Notes
▲Debt Royalty FinancingCorporate
Issuance of $225M 4.625% Convertible Senior Notes due 2031, including exchange for 2027 notes and new money
▲Preclinical PoCPreclinical
Preclinical data published in Nature Communications showing immunogenicity of H5N1 vaccine candidate in nonhuman primates
avian pandemic influenzasource ↗
▲Preclinical PoCPreclinical
Preclinical data published in Nature Communications for H5N1 avian pandemic influenza vaccine candidate
H5N1 avian influenzasource ↗
◆Timing GuidanceCICPresentation
Potential Accelerated Approval filings
COVID-19 and influenza combinationsource ↗
◆Oral PresentationPresentation
Goldman Sachs 46th Annual Global Healthcare Conference Presentation
▲Topline ReadoutClinical Data
Initial cohort of Phase 3 trial for CIC showed robust immune responses and was well tolerated
COVID-19 and influenzasource ↗
▲Topline Readouttrivalent hemagglutinin nanoparticle seasonal influenzaClinical Data
Initial cohort of Phase 3 trial for tNIV showed robust immune responses and was well tolerated
Influenzasource ↗
Past FDA Catalysts and PDUFA Decisions
How NVAX actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2021-03-31 | NVX-CoV2373 | Phase 3 interim results | Phase 3 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
B60 / 100
Pipeline Score
$6.5B
Pipeline Value
$1.8B
Commercial Value
Undervalued
Valuation Signal
10
Drugs Scored
10.3x
rNPV / MCap
Top 7%
Small Cap(rank 47 of 660)
Percentile Rank
Novavax, Inc. holds a solid B-grade pipeline (60/100), with $10.0B risk-adjusted pipeline value, led by SARS-CoV-2 rS/Matrix-M Adjuvant- Phase 1 in SARS-CoV-2 Infection (Phase 3), across $88B in total addressable markets.
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $413.8M x 4.4 = $1.8B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| Nuvaxovid | $29M | $694M | -95.8% |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| SARS-CoV-2 rS/Matrix-M Adjuvant- Phase 1 VaccineCompletedNCT04611802 | SARS-CoV Infection | Phase 3 | COMPLETED | 33,000 | Dec 15, 2023 |
Clinical Trial Results
Readouts, endpoints and source filings for every NVAX program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| COVID-19-Influenza Combination and stand-alone trivalent hemagglutinin nanoparticle seasonal influenza | COVID-19 and Influenza | Phase 3 | 2025-06-11 | 2.4-5.7-fold over baselineRead More | Novavax's COVID-19-Influenza Combination and Stand-alone Influenza Vaccine Candidates Showed Robust Immune Responses and Were Well Tolerated in Initial Cohort of a Phase 3 Trial Both vaccine candidates induRead More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Rodgers Richard JDirector | Option | 18,880 47,370 held | $0.00 | 06/20/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in NVAX
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| Deep Track Capital, LP | 0.2 % (-33.3 %) | 6.29 M | 998.54 K | -34.23% ( -519.64 K) |
NVAX Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-16 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How NVAX ranks across every disease it competes in
Competitive Position is a premium feature
See how NVAX ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialNVAX News
NVAXNovavax to Participate in September Investor Conferences
Novavax, Inc. announced its participation in two upcoming investor conferences in September 2026. The events include the Cantor Global Healthcare Conference and Citi's BioPharma Back to School Conference, both in New York. Live webcasts of the presentations will be available, with replays accessible for 30 days post-event.
Read more →NVAXNovavax's Partnership Strategy Continues to Deliver with XFG-adapted Nuvaxovid™ Approvals in the U.S., EU and Japan for 2026-2027 Vaccination Season
Novavax's Nuvaxovid vaccine has received approvals for the 2026-2027 vaccination season in the U.S., EU, and Japan, targeting the SARS-CoV-2 XFG variant. The company benefits from partnerships with Sanofi and Takeda, which are expected to enhance its market presence. The vaccine's favorable tolerability profile was highlighted in a recent study, reinforcing its position as a viable option for healthcare providers.
Read more →NVAXNovavax Reports Second Quarter 2026 Financial Results and Operational Highlights
Novavax reported a total revenue of $57 million for Q2 2026, a significant decline from $239 million in Q2 2025. The company improved its financial guidance for the year, particularly in R&D and SG&A expenses. Notably, the partnership with Sanofi is progressing, with upcoming milestones that could enhance revenue. However, Novavax also faced a net loss of $53 million, reflecting challenges in revenue generation.
Read more →NVAXNovavax to Report Second Quarter 2026 Financial Results on August 6, 2026
Novavax, Inc. will release its second quarter 2026 financial results on August 6, 2026, before the U.S. markets open. Following the release, management will host a conference call and webcast at 8:30 a.m. ET to discuss the results and operational highlights. Participants can register online for the call and access a replay afterward.
Read more →NVAXNovavax to Participate in 2026 Jefferies Global Healthcare Conference
Novavax, Inc. has announced its participation in the 2026 Jefferies Global Healthcare Conference. The event will feature a fireside chat, with a webcast available for 30 days on the company's website. This participation highlights Novavax's commitment to addressing global health challenges through its innovative vaccine technologies.
Read more →NVAXNovavax to Participate in BofA Securities 2026 Health Care Conference
Novavax, Inc. announced its participation in the BofA Securities 2026 Health Care Conference, scheduled for May 13, 2026. The event includes a fireside chat and investor meetings, highlighting the company's ongoing engagement with stakeholders. A webcast of the chat will be available for 30 days post-event.
Read more →NVAX▲ +15.6%on this newsshared move
Novavax Reports First Quarter 2026 Financial Results and Operational Highlights
Novavax, Inc. reported its financial results for Q1 2026, highlighting significant progress in its corporate strategy, including a new licensing agreement with Pfizer for vaccine candidates. The company is also advancing its C. difficile vaccine candidate towards clinical trials. However, its revenue projections depend on Sanofi's forecasts, and regulatory approval uncertainties remain a concern.
Read more →NVAXNovavax to Report First Quarter 2026 Financial Results on May 6, 2026
Novavax, Inc. will announce its first quarter 2026 financial results on May 6, 2026, at 8:30 a.m. ET. The company will host a conference call to discuss operational highlights, with details available for participants to join. A replay of the call will be accessible for a limited time after the event.
Read more →NVAXNovavax Appoints Dr. Robert Walker as Executive Vice President and Head of Research & Development
Novavax has appointed Dr. Robert Walker as the new Executive Vice President and Head of R&D. Dr. Walker brings over 30 years of experience in drug and vaccine development, having previously served as Chief Medical Officer at Novavax. His appointment is seen as a strategic move to enhance the company's research and development capabilities.
Read more →NVAX▼ -9.4%on this news
Novavax to Participate in Upcoming Investor Conferences
Novavax, Inc. has announced its participation in several upcoming investor conferences. The company will provide webcasts of the events, which will be accessible on its website for 30 days. This initiative reflects Novavax's commitment to engaging with investors and sharing insights about its vaccine technology and growth strategies.
Read more →NVAX▲ +17.4%on this newsshared move
Novavax Reports Fourth Quarter and Full Year 2025 Financial Results and Operational Highlights
Novavax, Inc. reported its financial results for Q4 and the full year 2025, highlighting significant progress in corporate strategy and partnerships. The company anticipates a revenue range of $230 million to $270 million for 2026, driven by collaborations with Sanofi and Pfizer. However, it faces challenges related to regulatory approvals and market acceptance of its vaccine candidates.
Read more →NVAX▲ +6.2%on this news
Novavax to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026
Novavax, Inc. (Nasdaq: NVAX) announced that it will report its fourth quarter and full year 2025 financial results on February 26, 2026. The event will be accessible via a conference call starting at 8:30 a.m. Eastern Time. Replay details for the event and instructions for registration have also been provided, allowing stakeholders to participate or access the information later. Novavax aims to enhance its impact through cutting-edge vaccine technology and strategic partnerships.
Read more →NVAXNovavax Announces Entering into a License Agreement with Pfizer
Novavax has entered into a license agreement with Pfizer for its Matrix-M adjuvant, allowing Pfizer to use this technology in up to two disease areas. CEO John C. Jacobs expressed optimism about the partnership, indicating it reflects the potential of Matrix-M in new product development. However, the agreement comes with various risks and uncertainties regarding implementation and regulatory approval.
Read more →NVAX▲ +6.6%on this news· ran to +19% by day 1
xA9; 2026 NOVAVAX. All rights reserved. 1 Novavax Corporate Presentation John C. Jacobs, President and Chief Executive Officer J.P. Morgan Healthcare Conference © 2026 NOVAVAX. All rights reserved. 1 © 2026 NOV
Novavax has outlined several challenges it faces in its corporate presentation, particularly concerning obtaining necessary regulatory approvals for its COVID-19 vaccine. The company has emphasized potential risks including delays in manufacturing, supply chain issues, and the impact of external partnerships. Investors are warned against placing heavy reliance on forward-looking statements due to these uncertainties. Additionally, the presentation mentions challenges in securing funding for ongoing operations and further development of vaccine candidates.
Read more →NVAXNovavax to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Novavax, Inc. has announced its participation in the 44th Annual J.P. Morgan Healthcare Conference. The event will feature a webcast of their presentation, available for 30 days post-event. The company aims to tackle global health challenges through its innovative vaccine technology and seeks to expand its partnerships and research efforts.
Read more →NVAXNovavax to Participate in Jefferies London Healthcare Conference
Novavax, Inc. has announced its participation in the Jefferies London Healthcare Conference scheduled for November 19, 2025. The event will feature a fireside chat at 4:30 p.m. GMT, which will also be available via webcast. This participation highlights Novavax's ongoing efforts to engage with investors and share insights into its vaccine development initiatives.
Read more →NVAXNovavax Reports Third Quarter 2025 Financial Results and Operational Highlights
Novavax, Inc. has reported its financial results for Q3 2025, highlighting a strategic focus on R&D and partnerships aimed at long-term growth. Despite a significant drop in total revenue and Nuvaxovid sales, the company is prioritizing the optimization of its partnership with Sanofi and advancing its technology platform. The net loss for the quarter was $202.4 million.
Read more →NVAX▼ -5.1%on this newsshared move
Novavax Completes U.S. Marketing Authorization Transfer to Sanofi for Nuvaxovid™, Triggering a $25 Million Milestone Payment
Novavax has successfully transferred the U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid™, to Sanofi, which will now manage commercial and regulatory activities in the U.S. This transfer has triggered a $25 million milestone payment to Novavax, contributing to a total of $225 million in milestone revenue. Novavax remains eligible for additional future milestones and royalties under their collaboration agreement with Sanofi.
Read more →NVAX▼ -5.1%on this newsshared move
Novavax Completes U.S. Marketing Authorization
Novavax has completed the transfer of U.S. marketing authorization for its COVID-19 vaccine, Nuvaxovid, to Sanofi, allowing Sanofi to manage commercialization in the U.S. This transfer triggered a $25 million milestone payment for Novavax, following a similar transfer to the European Union. With this, Novavax has secured $225 million in milestone revenue to date. Additionally, Novavax is eligible for future milestone payments under its collaboration with Sanofi, which may include royalties and new product opportunities.
Read more →About Novavax, Inc.
Headquarters21 FIRSTFIELD RD, GAITHERSBURG, MD
BIOPHARMAWATCH ELITE PLUS
Trade the next NVAX catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime